Roche has announced the market availability of the Elecsys® Syphilis immunoassay, a diagnostic test to help detect patients infected with syphilis in routine clinical practice and to make sure donated blood is not infected with syphilis.
Although most new syphilis cases occur in developing countries, syphilis has re-emerged as a health concern in a number of developed nations over the past decade. Designed for the emerging needs of clinical laboratories for reliable and efficient detection of this disease the test enhances Roche’s solutions portfolio in serology testing - the testing of antibodies formed as a response to an infection - and complements the most comprehensive offering for blood safety available on the market today.
“Every year 12 million people get infected with syphilis worldwide. To test for syphilis at the early stage is important when the disease is still curable and it is essential that blood donations are free of syphilis pathogens when given to patients,” said Roland Diggelmann, Chief Operating Officer of the Roche Diagnostics Division. “We strive for continual improvement to meet laboratories’ and blood banks’ evolving needs, expanding our menu offering and providing integrated solutions to improve testing reliability, safety and efficiency.”
Thanks to its high sensitivity, the test minimizes the likelihood of missing syphilis infections, enabling healthcare professionals in laboratories to efficiently run a single test within 18 minutes, ensuring the safe and timely supply of blood products.
Moreover, its high specificity facilitates a clear and consistent interpretation of results at all disease stages with a minimal need for re-testing, providing maximum efficiency gains for the laboratory and patient safety.